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the CSF and the adjacent brain tissue. Long-term neu-
rological sequelae and death are caused jointly by the
following factors: (1) The systemic inﬂammatory response
of the host leads to leukocyte extravasation into the sub-
arachnoid space, an increased CSF outﬂow resistance, and
brain edema. The resulting elevated intracranial pressure
is an important cause of death in the acute phase and
of long-term sequelae. Systemic inﬂammation can also
cause vasculitis, cerebral venous thrombosis and secondary
ischemia. (2) Immune cells within the brain parenchyma,
in particular microglia, can be stimulated by proinﬂam-
matory bacterial compounds, which can directly lead to
neuronal injury. (3) Some bacterial compounds, e.g., pneu-
molysin, possess direct toxicity on neurons. Neuronal injury
is mediated by the release of reactive oxygen intermedi-
ates, proteases, cytokines and excitatory amino acids, the
activation of transcription factors, caspases, matrix metal-
loproteases and other proteases.
Rapid initiation of effective antibiotic therapy sterilizes
the CSF and reduces mortality of bacterial meningitis. In
industrialized countries, dexamethasone as an adjunctive
therapy to antibiotic treatment, improves outcome of bac-
terial meningitis, particularly of Streptococcus pneumoniae
meningitis. In experimental meningitis, dexamethasone as
an adjunct to antibiotic treatment causes an increase of
neuronal injury in the dentate gyrus of the hippocampal
formation, suggesting that corticosteroids might not be the
ideal adjunctive therapy. Several approaches that inter-
fere selectively with the mechanisms of neuronal injury,
including the use of non-bacteriolytic bactericidal protein
synthesis-inhibiting antibiotics, antioxidants and inhibitors
of transcription factors, matrix metalloproteinases, and cas-
pases, are effective in animal models. However, adequate
clinical studies are lacking. A recent randomized clinical
study points to a beneﬁcial effect of adjunctive oral glyc-
erol.
doi:10.1016/j.ijid.2010.02.2228
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Thanks to conjugate vaccines specially against
Haemophilus inﬂuenzae (Hib) and Streptococcus pneu-
moniae (Pnc), bacterial meningitis has become disease
whose global importance is no more realized in the afﬂuent
countries. However, more than 1 MI individuals a year,
proportionally more often children than adults, fall down;
one-third succumb, and one-third of survivors are left
with moderate-to-severe sequelae. In the world where the
meningitis problem is greatest, only a fraction of people
are vaccinated. The main (though not only) reason is the
too high cost of conjugates for those populations.
Years ago, inexpensive polysaccharide vaccines were
developed against Hib, Pnc, and Neisseria meningitidis
(Mnc). The Hib, polysaccharide is rightly gone, but all poten-
tial of polysaccharides against Pnc and Mnc has not been
used. The reasoning is that polysaccharides are not suf-
ﬁciently immunogenic in small children (in greatest risk).
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owever, convincing clinical efﬁcacy data are lacking to
rove this statement. It is unlikely that those data will ever
e produced, because people are too convinced of the supe-
iority of conjugates to support any major ﬁeld trial with a
nc or Mnc polysaccharide.
At present, variable conjugate vaccines are available
gainst Hib, 7-13 serotypes of Pnc, and up to 4 serogroups of
nc. Hib vaccination is indicated in all countries. So is also
nc conjugate, albeit its effect speciﬁcally against meningi-
is depends on local epidemiology (serotype distribution).
n case of Mnc meningitis, the main problem is the lack
f sufﬁciently good vaccine against serogroup B, the most
ommon group in many countries. Fortunately, encouraging
esults have been obtained recently regarding a new-type
f vaccine.
Group A Mnc is a special problem of Africa. Monovalent
onjugate has been used there, and luckily, its price is tol-
rable because of its manufacturing outside Big Farma. This
pproach would be welcome to cover other causative agents
f meningits as well.
oi:10.1016/j.ijid.2010.02.2229
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Objective: To review advances in adjuvant therapy of
acterial meningitis.
Data Sources: Work published within past 5 years
etrieved from personal knowledge and the U.S. National
ibrary of Medicine for terms: central nervous system infec-
ions, meningitisbacterial; therapy; corticosteroids; ﬂuids;
nti-inﬂammatory; glycerol, and pediatrics.
Study Selection, Data Extraction and Synthesis: Promis-
ng articles were reviewed and data used based on clinical
elevance and signiﬁcance.
Results: Corticosteroid therapy: Results from clinical
rials of adjuvant steroid therapy are conﬂicting. What
merges from meta-analysis is that in high-income countries
teroids reduce the risk of hearing loss in immunocompetent
atients with H. inﬂuenzae-b or pneumococcal meningitis;
here is no survival beneﬁt. In low-income countries utility
f corticosteroids is unclear.
Fluids: Evidence supports normal maintenance intra-
enous ﬂuids rather than restricted ﬂuids in the ﬁrst 48 hours
n settings; it reduces risk of spasticity and severe neurologic
equelae.
Oral glycerol therapy during ﬁrst 48 hours of treatment
an prevent severe neurologic sequelae. Within 6 hours of
dministration oral glycerol increased plasma osmolality by
%, which is known to reduce secretion of CSF and enhance
ovement of water back to plasma, and thus improve cere-
ral blood ﬂow.
Management of raised ICP is not easy because a variety
f mechanisms. Neuroimaging may be helpful in selection
f appropriate treatment. Cerebral perfusion pressure tar-
eted therapy to maintain CPP >50mmHg is likely to improve
he outcome.
